



ANNOUNCEMENT
SUMMARY OF MINUTES OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
FOR FINANCIAL YEAR 2024
PT KIMIA FARMA Tbk

The Board of Directors of PT Kimia Farma Tbk (hereinafter referred to as the “**Company**”), having its domicile in Central Jakarta, hereby announces that the Company has convened the Annual General Meeting of Shareholders (hereinafter referred to as the “**Meeting**”) on:

Day/Date : Wednesday, July 30, 2025
Time : 17.49 WIB – 21.04 WIB
Venue : *Indonesia Health Learning Institute*
Jalan Cipinang Cempedak I No. 36,
Jatinegara, Jakarta Timur.

The Meeting was chaired by Mr. Stefan Looho as President Commissioner of the Company based on the resolution of the Board of Commissioners Number: KEP-002/KOM-KF/VII/2025 dated July 10, 2025, regarding the Appointment of the Chairperson of the Annual General Meeting of Shareholders of PT Kimia Farma Tbk for Financial Year 2024.

A. Attendance of Board of Commissioners and Board of Directors

The Meeting was physically attended by 5 (five) members of the Board of Commissioners and 6 (six) members of the Board of Directors as follows:

Board of Commissioners		Board of Directors	
President Commissioner, concurrently serving as Independent Commissioner	Mr. Stefan Looho	President Director	Mr. Djagad Prakarsa Dwialam
Commissioner	Mr. Wiku Adisasmito	Director of Financial & Risk Management	Mrs. Lina Sari
Independent Commissioner	Mrs. Diah Kusumawardani	Director of Portfolio, Product, and Service	Mrs. Jasmine Kamiasti Karsono
Independent Commissioner	Mr. Fachmi Idris	Director of Commercial	Mrs. Chairani Harahap
Commissioner	Mr. Suprianto	Director of Production and Supply Chain,	Mr. Hadi Kardoko
		Director of Human Resources	Mr. Disril Revolin Putra

B. Attendance Quorum of the Shareholders

Based on Article 25 paragraph (1) of the Company's Articles of Association and Article 86 paragraph (1) of Law Number 40 of 2007 concerning Limited Liability Companies, for the **Agenda Items 1, 2, 3, 4, 5, and 6**, the Meeting can be held if attended by shareholders representing more than $\frac{1}{2}$ (one half) of the total number of shares with valid voting rights.

Based on Article 25 paragraph (4) of the Company's Articles of Association and Article 86 paragraph (1) of Law Number 40 of 2007 concerning Limited Liability Companies, for **Agenda Item 7**, the meeting can be held if attended by the Series A Dwiwarna Shareholders and other Shareholders and/or their valid representatives together representing more than $\frac{1}{2}$ (one half) of the total number of shares with valid voting rights.

Based on the Register of Shareholders as of the Recording Date on **Friday, July 4, 2025**, and the Attendance List from PT Datindo Entrycom as the Company's Securities Administration Bureau, the meeting was attended by the Shareholders and/or their proxies, both physically and via e-Proxy eASY.KSEI, representing a total of 5.246.575.200 (five billion two hundred forty-six million five hundred seventy-five thousand two hundred) shares, including the Series A Dwiwarna shares, or 94,2511789% (ninety-four point two five one one seven eight nine percent) of 5.566.584.590 (five billion five hundred sixty-six million five hundred eighty-four thousand five hundred ninety) shares, which is the total number of shares with valid voting rights issued by the Company as of the date of the Meeting, consisting of:

- 1 (one) series A Dwiwarna share; and
- 5.566.584.589 (five billion five hundred sixty-six million five hundred eighty-four thousand five hundred eighty-nine) series B shares.

C. Meeting Agendas Brief Explanation

1. Board of Directors report on the Delay of the General Meeting of Shareholders for the Financial Year 2024.

Brief Explanation:

Based on Article 78 of Law No. 40 of 2007 concerning Limited Liability Companies, Article 2 paragraph (2) of the Financial Services Authority Regulation Number 15/POJK.04/2020 of 2020 concerning the Plan and Organizing of the General Meeting of Shareholders of a Public Company, and Article 21 of the Company's Articles of Association, annual General Meeting of Shareholders shall be convened no later than 6 months after the end of the financial year.

In relation to the ongoing preparation process of the Annual Consolidated Financial Statements (LKT) for the 2024 Financial Year, which extended beyond the deadline for holding the Annual General Meeting of Shareholders (AGMS), the Company convened the Meeting only on Wednesday, July 30, 2025

2. **Approval of the Company's Annual Report and Ratification of the Company's Consolidated Financial Statements of the Financial Year 2024, Approval of the Supervisory Report of the Board of Commissioners for the Financial Year 2024, including the Ratification of the Re-Issue and the Restatement of the Consolidated Financial Statements for Financial Year of 2023, and Ratification of the Implementation Report of the Micro and Small Business Funding Program (PUMK) for the Financial Year 2024, as well as the Granting of Full Discharge and Release of Responsibility (*volledig acquit et de charge*) to the Board of Directors for the Management Actions of the Company and the Board of Commissioners for the Supervisory Actions of the Company carried out during the Financial Year 2024 and Re-Issue and Restatement of Consolidated Financial Statements for Financial Year 2023.**

Brief Explanation:

1. *Under Article 18 Paragraph (9) of the Company's Article of Association and Law Number 40 of 2007 concerning Limited Liability Companies (Company Law), it is stated that:*
 - a) *The Board of Directors submits an annual report to the General Meeting of Shareholders (GMS) after being reviewed by the Board of Commissioners;*
 - b) *The GMS carries out the approval of the Annual Report, including the ratification of the financial statement and the Board of Commissioners' supervisory report.*
2. *Under the Article 33 paragraph (1) of the Regulation of the Minister of State-Owned Enterprises ("Permen BUMN") Number PER 1/MBU/03/2023 concerning the Special Assignment and the Social and Environmental Responsibility Program of State-Owned Enterprises ("TJSL") ("**PerMen BUMN No. 1 of 2023**") which stipulates that financial statements and report of the implementation of the TJSL Program are integrated into the quarterly report and annual report on the performance of the State-Owned Enterprise outlined in a separate chapter.*

3. **Approval of the Use of the Company's Net Profit for the Financial Year 2024.**

Brief Explanation:

Based on the Company's Articles of Association, the Board of Directors submits a proposal for the use of the Company's Net Profit.

4. **Determination of Salary/Honorarium along with Facilities and Allowances for the Financial Year 2025 and Tantiem/Performance Incentives/Special Incentives for the Performance of Financial Year 2024 for Board of Directors and Board of Commissioners.**

Brief Explanation:

Based on the Company's Articles of Association, it is stated that the Salary/Honorarium, Allowances, and Facilities for the Board of Commissioners and the Board of Directors, as well as bonuses, must be decided by the GMS and the GMS can delegate the authority to determine them to the majority Series B Shareholders

5. **Approval of Appointment of the Public Accounting Firm (KAP) to audit the Company's Consolidated Financial Statements of the Company Financial Year 2025 and the Financial Statements of the Micro and Small Business Funding Program (PUMK) Report for the Financial Year 2025.**

Brief Explanation:

Based on Article 59 paragraph (1) of the Financial Services Authority Regulation Number 15/POJK.04/2020 concerning the Plan and Organizing of the General Meeting of Shareholders of a Public Company, it is stated that the Appointment and Dismissal of

Public Accountants and/or Public Accounting Firms that will provide audit services for information Annual historical financial statements must be decided in the GMS of a Public Company by considering the proposal of the Board of Commissioners.

6. Report on the Implementation of the Mandatory Convertible Bonds (OWK) Conversion into Shares for the Purpose of Increasing the Company's Capital, and Approval to Grant Authority to the Company's Board of Commissioners to Determine the Amount of Issued and Paid-up Capital Increase.

Brief Explanation:

Based on Article 41 paragraphs (1) and (2) of the Law Number 40 of 2007 concerning Limited Liability Companies (Company Law), it is regulated as follows:

- (1) The increase in the Company's capital is carried out based on the approval of the GMS.*
- (2) The GMS may delegate authority to the Board of Commissioners to approve the implementation of the GMS decisions as referred to in paragraph (1) for a maximum period of 1 (one) year.*

7. Changes in the Company's Management Composition.

Brief Explanation:

- (1) Changes in the composition of the Company's Management based on the resolutions of the Annual General Meeting of Shareholders (AGMS) for the Financial Year 2019 on July 29, 2020, regarding the term of office of the Independent Commissioner (Mr. Musthofa Fauzi), which term (5 years) will end at the AGMS for the Financial Year 2024 for the first term and may subsequently be reappointed by the GMS.*
- (2) Based on the Company's Article of Association, the Board of Directors and the Board of Commissioners are appointed and dismissed by the GMS.*

D. Opportunity for Discussion

1. Each Meeting Agenda is given the opportunity to ask questions.
2. Shareholders or their proxies have 3 (three) opportunities to submit questions and/or opinions at each discussion session in each Meeting Agenda.
3. Submission of questions and/or opinions submitted orally cannot be responded to.
4. The Chairperson of the Meeting may limit the time in the question-and-answer program for each Meeting Agenda.
5. The process for submitting questions and/or opinions for Shareholders who are physically present at the Meeting is as follows:
 - a. The Chairperson of the meeting will ask the shareholders if they have any questions or opinions to submit.
 - b. Questions and/or opinions that have been written by the Shareholders are submitted to the officer to be submitted to the Notary and Chairperson of the Meeting or the party appointed to provide an explanation.
6. The process of submitting questions and/or opinions for Shareholders electronically at the Meeting through eASY.KSEI, is as follows:
 - a. Questions and/or opinions are submitted through the chat feature in the 'Electronic Option' column available on the E-Meeting Hall screen at eASY.KSEI;

- b. Questions and/or opinions can be submitted as long as the 'General Meeting Flow Text' column has the status of "discussion started for agenda item no. [...]".
- 7. Provisions for submitting questions and/or opinions for Shareholders electronically at the Meeting are as follows:
 - a. Shareholders write their names, number of shares owned, as well as questions and/or opinions.
 - b. For the proxies, the written submission must be accompanied by a description of the name of the Shareholder and the size of their share ownership, followed by related questions and/or opinions.
- 8. Questions and/or opinions that have been submitted by the Shareholders or their proxies are then submitted to the Notary to examine their validity/authority.
- 9. Questions and/or opinions that have been examined by a Notary are submitted by officers to the Chairperson of the Meeting. The Chairperson of the Meeting will then read out the questions and/or opinions.
- 10. The Chairperson of the Meeting has the right to refuse to answer questions and/or opinions that are not related to the Meeting Agenda being discussed or that have been previously asked.
- 11. Members of the Board of Commissioners or members of the Board of Directors or parties appointed by the Chairperson of the Meeting will answer questions or respond to opinions that have been read out as referred to in point 9 above.
- 12. The Chairperson of the Meeting has the authority to take the necessary actions to maintain the orderliness of the Meeting.

E. Meeting Resolution Mechanism

1. Meeting decisions are taken based on deliberation to reach a consensus. In the event that the Meeting decisions based on deliberation to reach a consensus is not reached, then the decision shall be taken by voting, with the following conditions:

Based on Article 25 paragraph (1) of the Company's Articles of Association and Article 87 paragraph (2) of Law Number 40 of 2007 concerning Limited Liability Companies, for the **Agenda Items 1, 2, 3, 4, And 6**, a resolution is valid if approved by more than $\frac{1}{2}$ (one half) of the total number of shares with valid voting rights present at the meeting.

Based on Article 25 paragraph (4) of the Company's Articles of Association and Article 87 paragraph (2) of Law Number 40 of 2007 concerning Limited Liability Companies, for **Agenda Item 7**, a resolution is valid if approved by the Series A Dwiwarna Shareholders and other Shareholders and/or their valid representatives together representing more than $\frac{1}{2}$ (one half) of the total number of shares with valid voting rights present at the meeting.

2. Voting is conducted after all the questions have been answered and/or the question-and-answer time has expired.
3. Each share gives the holder the right to cast 1 (one) vote. If a Shareholder owns more than 1 (one) share, he/she is only required to give 1 (one) time and the vote represents all shares that he owns or represents.
4. Voting for Meeting resolutions shall be conducted by "Raising Hands" with the following conditions:

- a. Those who Disagree and Abstain will be asked to raise their hand and submit their ballot card;
 - b. Those who did not raise their hands were deemed to vote in agreement;
 - c. The vote of abstention is deemed to have issued the same vote as the vote of the majority of shareholders who cast a vote;
 - d. For each Agenda of the Meeting, voting will be carried out for decision-making;
 - e. At the end of each voting, the Notary reads the results of the voting.
5. The voting process for Shareholders electronically in the Meeting through eASY.KSEI (e-Voting) is carried out with the following procedure:
- a. The voting process takes place at eASY.KSEI on the E–Meeting Hall menu, Live Broadcasting sub menu;
 - b. Shareholders who attend or provide power of attorney electronically at the Meeting through eASY.KSEI, who have not yet made their vote, have the opportunity to submit their vote during the voting period through the E-Meeting Hall screen at eASY.KSEI;
 - c. During the voting process, the ‘General Meeting Flow Text’ column will show the status of “voting for agenda item no, [...] has started”.
 - d. If the Shareholders do not vote for the Meeting Agenda until the status of the Meeting as shown in the ‘General Meeting Flow Text’ column changes to “voting for agenda item no [...] has ended”, then the Shareholders are considered abstained;
 - e. Electronic direct voting per Meeting Agenda through eASY.KSEI is allocated a maximum of 5 (five) minutes.
6. Shareholders with valid voting rights who are present at the Meeting but abstain, in accordance with the provisions of Article 47 of POJK No. 15/POJK.04/2020 and Article 25 paragraph (11) of the Articles of Association are deemed to have cast the same vote as the majority vote of the shareholders who cast the vote.

F. Independent Party for Vote Counting

The Company has appointed independent parties, PT Datindo Entrycom to count and/or validate the votes.

G. Meeting Resolutions

The Meeting has resolved the following resolutions as set forth in the deed of “Minutes of the General Meeting of Shareholders of PT KIMIA FARMA Tbk abbreviated as PT KAEF Tbk.”, Number: **21** dated **July, 30 2025**, made before Notary Dewantari Handayani S.H., MPA., with its summary as follows:

First Meeting Agenda:

The Board of Directors report concerning the delay of the General Meeting of Shareholders for the Financial Year 2024

Number of Questioners

None of the Shareholders asked questions in the First Meeting Agenda.

Voting Calculations

DISAGREE	ABSTAIN	AGREE (Including the Series A Dwiwarna Shareholder)
20.200 shares or 0,0003850%	13.200 Shares or 0,0002516%	5.246.541.800 Shares or 99,9993634%

Thus, the Meeting, with a majority vote of 5.246.555.000 (five billion two hundred forty-six million five hundred fifty-five thousand) shares, representing 99,9996150% (ninety-nine point nine nine nine six one five zero percent) of the total votes cast at the Meeting, decided:

To accept the Board of Directors report of the postponement of the General Meeting of Shareholders for Financial Year 2024.

Second Meeting Agenda:

Approval of the Company's Annual Report and Ratification of the Company's Consolidated Financial Statements of the Financial Year 2024, Approval of the Supervisory Report of the Board of Commissioners for the Financial Year 2024, including the Ratification of the Re-Issue and the Restatement of the Consolidated Financial Statements for Financial Year of 2023, and Ratification of the Implementation Report of the Micro and Small Business Funding Program (PUMK) for the Financial Year 2024, as well as the Granting of Full Discharge and Release of Responsibility (*volledig acquit et de charge*) to the Board of Directors for the Management Actions of the Company and the Board of Commissioners for the Supervisory Actions of the Company carried out during the Financial Year 2024 and Re-Issue and Restatement of Consolidated Financial Statements for Financial Year 2023.

Number of Questioners

None of the Shareholders asked questions in the Second Meeting Agenda.

Voting Calculations

DISAGREE	ABSTAIN	AGREE (Including the Series A Dwiwarna Shareholder)
20.100 Shares or 0,0003831%	13.200 Shares or 0,0002516%	5.246.541.900 Shares or 99,9993653 %

Thus, the Meeting, with a majority vote of 5.246.555.100 (five billion two hundred forty-six million five hundred fifty-five thousand one hundred) shares, representing 99,9996169% (ninety-nine point nine nine nine six one six nine percent) of the total votes cast at the Meeting, decided:

1. Approved the Company's Annual Report including the Board of Commissioners' Supervisory Duties Report for the Financial Year ended on December 31, 2024.

2. To Ratify:
 - a. The Company's Consolidated Financial Statements for the 2024 Financial Year ended on December 31, 2024, as audited by Public Accounting Firm Heliantono & Rekan pursuant to its report No. 01074/2.0459/AU.1/04/0916–1/1/VII/2025 dated July 7, 2025, which rendered an **“Unqualified Opinion, in all material respects”**.
 - b. The Reissuance of the Company's Financial Statements for the 2023 Financial Year ended on December 31, 2023, as audited by Public Accounting Firm Hendrawinata, Hanny, Erwin & Sumargo pursuant to its report No. 00274/2.1127/AU.1/04/0797-3/1/VI/2025 dated June 17, 2025, which rendered an **“Unqualified Opinion, in all material respects”**.
 - c. The Financial Statements of the Micro and Small Business Funding Program for the 2024 Financial Year ended on December 31, 2024, which form part of the Social and Environmental Responsibility Report, as audited by Public Accounting Firm Heliantono & Rekan pursuant to its report No. 00846/2.0459/AU.2/04/0916–1/1/V/2025 dated May 26, 2025, which rendered an **“Unqualified Opinion, in all material respects”**.
3. The Board of Directors and the Board of Commissioners are requested to thoroughly resolve the matters that have caused the recording of losses in the Company's Consolidated Financial Statements for the 2024 Financial Year and to remain consistently diligent and prudent in carrying out their duties and functions in order to optimize all resources of PT Kimia Farma Tbk for the comprehensive completion of the restructuring of PT Kimia Farma Tbk, with a view to maintaining the Company's business continuity.
4. With the approval of the Company's Annual Report, including the Supervisory Duties Report of the Board of Commissioners, and the ratification of the Company's Consolidated Financial Statements as well as the Financial Statements of the Micro and Small Business Funding Program (PUMK) for the 2024 Financial Year ended on December 31, 2024, the General Meeting of Shareholders hereby grants full release and discharge (*acquitt et de charge*) to all members of the Board of Directors for their management actions and to all members of the Board of Commissioners for their supervisory actions performed during the 2024 Financial Year ended on December 31, 2024, to the extent that such actions do not constitute criminal acts and/or violate the prevailing laws and regulations or applicable legal procedures, and are duly reflected in the Company's records.

Third Meeting Agenda

Approval of the Use of the Company's Net Profit for the Financial Year 2024.

Number of Questioners

None of the Shareholders asked questions in the Third Meeting Agenda.

Voting Calculations

DISAGREE	ABSTAIN	AGREE (Including the Series A Dwiwarna Shareholder)
20.200 Shares or 0,0003850%	13.200 Shares or 0,0002516%	5.246.541.800 Shares or 99,9993634%

Thus, the meeting with majority votes of 5.246.555.000 (five billion two hundred forty-six million five hundred fifty-five thousand) shares or are 99,9996150% (ninety-nine point nine nine nine six one five zero percent) of the total number of votes cast in the Meeting decided:

There will be no determination of the appropriation of the Company's net profit as the Company recorded a net loss in the Financial Year 2024.

Fourth Meeting Agenda

Determination of Salary/Honorarium along with Facilities and Allowances for the Financial Year 2025 and Tantiem/Performance Incentives/Special Incentives for the Performance of Financial Year 2024 for Board of Directors and Board of Commissioners.

Number of Questioners

None of the Shareholders asked questions in the Fourth Meeting Agenda.

Voting Calculations

DISAGREE	ABSTAIN	AGREE (Including the Series A Dwiwarna Shareholder)
20.200 Shares or 0,0003850%	13.200 Shares or 0,0002516%	5.246.541.800 Shares or 99,9993634%

Thus, the meeting with majority votes of 5.246.555.000 (five billion two hundred forty-six million five hundred fifty-five thousand) shares or are 99,9996150% (ninety-nine point nine nine nine six one five zero percent) of the total number of votes cast in the Meeting decided:

1. To grant authority and power of attorney to PT Bio Farma (Persero) as the holder of Series B Shares, upon prior consultation with the holder of the Series A Dwiwarna Share, to determine for the members of the Board of Commissioners:
 - a. Performance incentives/special incentives for the 2024 Financial Year; and
 - b. Salaries/honorarium, allowances, and facilities for the 2025 Financial Year.

2. To grant authority and power of attorney to the Company's Board of Commissioners, upon obtaining prior written approval from PT Bio Farma (Persero) as the holder of Series B Shares and after consultation with the Ministry of State-Owned Enterprises as the institution holding the Series A Dwiwarna Share, to determine for the members of the Board of Directors:
 - a. Performance incentives/special incentives for the 2024 Financial Year; and
 - b. Salaries/honorarium, allowances, and facilities for the 2025 Financial Year.

Fifth Meeting Agenda

Approval of the Appointment of the Public Accounting Firm (KAP) to audit the Company's Consolidated Financial Statements of the Company Financial Year 2025 and the Financial Statements of the Micro and Small Business Funding Program (PUMK) Report for the Financial Year 2025.

Number of Questioners

None of the Shareholders asked questions in the Fifth Meeting Agenda.

Voting Calculations

DISAGREE	ABSTAIN	AGREE (Including the Series A Dwiwarna Shareholder)
20.200 Shares or 0,0003850%	13.200 Shares or 0,0002516%	5.246.541.800 Shares or 99,9993634%

Thus, the meeting with majority votes of 5.246.555.000 (five billion two hundred forty-six million five hundred fifty-five thousand) shares or are 99,9996150% (ninety-nine point nine nine nine six one five zero percent) of the total number of votes cast in the Meeting decided:

1. To appoint Public Accounting Firm (KAP) Heliantono & Rekan as the Public Accounting Firm that will audit the Company's Consolidated Financial Statements as well as the Financial Statements of the Micro and Small Business Funding Program and other reports for the 2025 Financial Year.
2. To delegate authority and power of attorney to the Company's Board of Commissioners, upon obtaining prior approval from the majority holder of Series B Shares, to determine the amount of audit service fees for the Public Accounting Firm as approved in Resolution number 1 (one) above and any necessary additions to the scope of work and other reasonable requirements for such Public Accounting Firm.
3. To delegate authority to the Company's Board of Commissioners, upon obtaining prior approval from the majority holder of Series B Shares, to determine:
 - a. A replacement Public Accounting Firm in the event that the appointed Public Accounting Firm is unable to continue or perform its duties for any reason; and
The terms, conditions of appointment, and honorarium for the replacement Public Accounting Firm.

Sixth Meeting Agenda

Report on the Implementation of the Mandatory Convertible Bonds (OWK) Conversion into Shares for the Purpose of Increasing the Company's Capital, and Approval to Grant Authority to the Company's Board of Commissioners to Determine the Amount of Issued and Paid-up Capital Increase.

Number of Questioners

None of the Shareholders asked questions in the Sixth Meeting Agenda.

Voting Calculations

DISAGREE	ABSTAIN	AGREE (Including the Series A Dwiwarna Shareholder)
20.200 Shares or 0,0003850%	13.200 Shares or 0,0002516%	5.246.541.800 Shares or 99,9993634%

Thus, the meeting with majority votes of 5.246.555.000 (five billion two hundred forty-six million five hundred fifty-five thousand) shares or are 99,9996150% (ninety-nine point nine nine nine six one five zero percent) of the total number of votes cast in the Meeting decided:

1. To acknowledge the Report on the Implementation of the Mandatory Convertible Bonds (OWK) Conversion into the Company's shares in the context of the Company's Capital Increase.
2. To approve the granting of power and authority to the Board of Commissioners of the Company to declare the amount of capital increase issued and paid up as a result of the implementation of the Company's Compulsory Convertible Bonds (OWK), namely in Article 4 Paragraph (2) and Article 4 Paragraph (3) of the Company's Articles of Association and to take all necessary actions in connection therewith by taking into account laws and regulations.
3. To grant an extension of power and authority to the Board of Commissioners of the Company, with the right of substitution, to set forth and state all matters resolved in this Meeting agenda item in a notarial deed and to submit it to the competent authorities in order to obtain approval and/or a receipt of notification of the amendment to the Articles of Association, and to take any and all actions deemed necessary and useful for such purposes, without any exception, including to make additions and/or amendments to such amendment to the Articles of Association should it be required.

Seventh Meeting Agenda

Changes in the Company's Management Composition.

Number of Questioners

None of the Shareholders asked questions in the Seventh Meeting Agenda.

Voting Calculations

DISAGREE	ABSTAINED	AGREE (including Dual Color Series A Shareholders)
20.200 Shares or 0,0003850%	13.200 Shares or 0,0002516%	5.246.541.800 Shares or 99,9993634%

Thus, the meeting with majority votes of 5.246.555.000 (five billion two hundred forty-six million five hundred fifty-five thousand) shares or are 99,9996150%(ninety-nine point nine nine nine six one five zero percent) of the total number of votes cast in the Meeting decided:

1. To approve and ratify the honorable discharge of Mr. Musthofa Fauzi from his position as the Company's Independent Commissioner, who was appointed pursuant to the resolution of the 2019 Financial Year Annual General Meeting of Shareholders dated July 30, 2020, effective as of July 30, 2025, with gratitude for his contributions of time and effort during his tenure in such position.
2. To approve the honorable discharge of Mrs. Chairani Harahap from her position as the Company's Commercial Director, who was appointed pursuant to the resolution of the 2022 Extraordinary General Meeting of Shareholders dated October 14, 2022, with gratitude for her contributions of time and effort during her tenure in such position.
3. To approve the appointment of Mr. Hanadi Setiarto as the Company's Commercial Director.
4. In view of the changes in the Company's Management as referred to in points 1, 2, and 3 above, the composition of the Company's Management shall therefore be as follows:

a. Board of Directors

No.	Position	Name
1.	President Director	Djagad Prakasa Dwialam
2.	Commercial Director	Hanadi Setiarto
3.	Human Resource Director	Disril Revolin Putra
4.	Portfolio, Product, and Services Director	Jasmine Kamiasti Karsono
5.	Finance and Risk Management Director	Lina Sari
6.	Production and Supply Chain Director	Hadi Kardoko

b. Board of Commissioners

No.	Position	Name
1.	President Commissioner concurrently serving as Independent Commissioner	Stefan Looho
2.	Independent Commissioner	Diah Kusumawardani
3.	Independent Commissioner	Fachmi Idris
4.	Commissioner	Wiku Adisasmito
5.	Commissioner	Suprianto

5. For the members of the Company's Board of Directors who are to be appointed as referred to in point 3 and who currently hold other positions that are prohibited by the prevailing laws and regulations from being concurrently held with the position of Director of a Subsidiary of a State-Owned Enterprise, such individuals must resign or be dismissed from such positions.

Jakarta, July 31, 2025
PT Kimia Farma Tbk
Management